# A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

> clinical trial · VERIFIED · 2026-08-17

Status: RECRUITING · Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. · Condition: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

- Company: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06927466

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.